Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Other Current Liabilities 3 year CAGR for the quarter ending September 30, 2023: -17.34%

Freeline Therapeutics Holdings Plc Other Current Liabilities 3 year CAGR is -17.34% for the quarter ending September 30, 2023. Other Current Liabilities are current liabilities that are not categorized under accounts payable, short-term debt, or current revenue deferred. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Freeline Therapeutics Holdings Plc Other Current Liabilities for the quarter ending September 30, 2022 was USD 9.58 M, a -22.15% change year over year.
Freeline Therapeutics Holdings Plc Other Current Liabilities for the quarter ending September 30, 2021 was USD 12.30 M, a 2,355.69% change year over year.
Freeline Therapeutics Holdings Plc Other Current Liabilities for the quarter ending September 30, 2020 was USD 501.00 K.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends